Lantheus Holdings

Historical price data

Lantheus Holdings is a commercial leader in the radiopharmaceutical space, built on a vertically integrated model spanning discovery through global sales. Its strategy is anchored by the commercial success of PYLARIFY®, a leading PSMA PET imaging agent for prostate cancer, and DEFINITY®, an established ultrasound contrast agent. The company is advancing a deep pipeline of approximately 40 programs, targeting expansion in radiopharmaceutical oncology and diagnostics, while leveraging its robust manufacturing and commercial infrastructure to drive growth. With a market cap of ~$4.8B, Lantheus is positioned as a key consolidator and innovator in the high-growth targeted radiopharmaceutical sector.

A fully integrated radiopharmaceutical platform encompassing targeted ligand discovery, radiochemistry, end-to-end manufacturing of isotopes and drug products, and a global commercial network, all aligned under the 'Find, Fight, Follow®' strategy.

Lantheus competes in PSMA PET diagnostics primarily against Telix's Illuccix®, holding a strong duopoly position. In radiopharmaceutical therapeutics, it faces formidable competition from Novartis's approved Pluvicto® and other well-funded entities like Eli Lilly (Point Biopharma) and Bayer. Its vertically integrated platform and diagnostic-therapeutic synergy are key differentiators.